U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination
You searched 8+ million full text articles

Try this search in 34+ million citations and abstracts

PMC Full-Text Search Results

Items: 1 to 20 of 1784

1.
Adolescent and young adult (AYA) patient involvement and engagement in European health care and research projects: expanding the scope of patient advocacy
U. Košir, F. Lysen, N. Unterecker, T. Deželak, E. Sturesson, I. Shakhnenko, D. Stark, K. Rizvi, A.-S. Darlington, L. Wee, W.T.A. van der Graaf, O. Husson
ESMO Open. 2025 Mar; 10(3): 104478. Published online 2025 Feb 24. doi: 10.1016/j.esmoop.2025.104478
PMCID:
PMC11908577
ArticlePDF–219K
2.
Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2
S. Stintzing, J. Tabernero, T. Satoh, A. Dasari, S. Lonardi, C. Eng, R. Garcia-Carbonero, E. Elez, T. Yoshino, A.F. Sobrero, J.C. Yao, S. Kasper, D. Arnold, E. Basic, M. Granold, M. Petschulies, L. Wu, Y.-C. Chung, L. Chen, Z. Yang, E. Van Cutsem
ESMO Open. 2025 Mar; 10(3): 104297. Published online 2025 Feb 21. doi: 10.1016/j.esmoop.2025.104297
PMCID:
PMC11904580
ArticlePDF–495K
3.
The genomic landscape of metastatic clear-cell renal cell carcinoma and its prognostic value: a comprehensive analysis of a large real-world clinico-genomic database
M. Rizzo, G. Pezzicoli, C. Porta, M. Povero, L. Pradelli, E. Sicari, V.S. Barbiero, C. Porta
ESMO Open. 2025 Mar; 10(3): 104294. Published online 2025 Feb 17. doi: 10.1016/j.esmoop.2025.104294
PMCID:
PMC11876921
ArticlePDF–620K
4.
First-in-human phase I study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of PF-07209960 in patients with advanced or metastatic solid tumors
A. Naing, M. McKean, L.S. Rosen, D. Sommerhalder, N.M. Shaik, I.-M. Wang, C. Le Corre, K.A. Kern, N.H. Mishra, S.K. Pal
ESMO Open. 2025 Mar; 10(3): 104291. Published online 2025 Feb 17. doi: 10.1016/j.esmoop.2025.104291
PMCID:
PMC11876874
ArticlePDF–441K
5.
Transarterial chemoembolisation with irinotecan (irinotecan-TACE) as salvage or post-inductive therapy for colorectal cancer liver metastases: effectiveness results from the CIREL study
D. Arnold, P.L. Pereira, R. Iezzi, A. Gjoreski, S. Spiliopoulos, T. Helmberger, F.M. Gomez, T. de Baère, O. Pellerin, G. Maleux, H. Prenen, B. Sangro, B. Zeka, N.C. Kaufmann, J. Taieb
ESMO Open. 2025 Mar; 10(3): 104292. Published online 2025 Feb 15. doi: 10.1016/j.esmoop.2025.104292
PMCID:
PMC11872576
ArticlePDF–1.1M
6.
ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma
R.L. Obermannová, T. Leong, ESMO Guidelines Committeegro.omse@senilediuglacinilc
ESMO Open. 2025 Feb; 10(2): 104134. Published online 2025 Feb 12. doi: 10.1016/j.esmoop.2025.104134
PMCID:
PMC11889489
ArticlePDF–427K
7.
High expression level of ERBB2 and efficacy of trastuzumab deruxtecan in desmoplastic small round cell tumour: a monocentric case series report
M. Brahmi, H. Vanacker, A. Dufresne, V. Isnardi, M. Dupont, A. Meurgey, M. Karanian, P. Meeus, M.-P. Sunyach, F. Tirode, J.-Y. Blay
ESMO Open. 2025 Feb; 10(2): 104133. Published online 2025 Feb 7. doi: 10.1016/j.esmoop.2025.104133
PMCID:
PMC11850745
ArticlePDF–1.2M
8.
Sinonasal malignancy: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up
C. Resteghini, B. Baujat, P. Bossi, A. Franchi, L. de Gabory, J. Halamkova, F. Haubner, J.A.U. Hardillo, M.A. Hermsen, N.A. Iacovelli, R. Maroldi, S. Mattheis, A. Moya-Plana, P. Nicolai, E. Orlandi, J. Thariat, A. Trama, M.W.M. van den Brekel, C.M.L. van Herpen, B. Verillaud, E. Kinloch, L. Licitra, C. Even, ESMO Guidelines Committeegro.omse@senilediuglacinilc
ESMO Open. 2025 Feb; 10(2): 104121. Published online 2025 Feb 6. doi: 10.1016/j.esmoop.2024.104121
PMCID:
PMC11889493
ArticlePDF–682K
9.
Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations
S.A. Piha-Paul, C. Tseng, H.T. Tran, A. Naing, E.E. Dumbrava, D.D. Karp, J. Rodon, T.A. Yap, K.P. Raghav, S. Damodaran, X. Le, P.T. Soliman, J. Lim, F. Meric-Bernstam
ESMO Open. 2025 Feb; 10(2): 104136. Published online 2025 Feb 4. doi: 10.1016/j.esmoop.2025.104136
PMCID:
PMC11847258
ArticlePDF–1.1M
10.
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study
C. Antoniotti, M. Carullo, D. Rossini, F. Pietrantonio, L. Salvatore, S. Lonardi, S. Tamberi, C. Sciortino, V. Conca, M.A. Calegari, P. Ciracì, E. Tamburini, F. Bergamo, C. Boccaccio, A. Passardi, G. Ritorto, C. Ugolini, G. Aprile, J. Galon, C. Cremolini
ESMO Open. 2025 Feb; 10(2): 104135. Published online 2025 Feb 4. doi: 10.1016/j.esmoop.2025.104135
PMCID:
PMC11847248
ArticlePDF–400K
11.
Interobserver consistency and diagnostic challenges in HER2-ultralow breast cancer: a multicenter study
S. Wu, J. Shang, Z. Li, H. Liu, X. Xu, Z. Zhang, Y. Wang, M. Zhao, M. Yue, J. He, J. Miao, Y. Sang, J. Yan, W. Pang, Q. Shao, Y. Zhang, M. Zhao, X. Liu, P. Wang, C. Cai, B. Liu, X. Wang, Y. Liu
ESMO Open. 2025 Feb; 10(2): 104127. Published online 2025 Jan 31. doi: 10.1016/j.esmoop.2024.104127
PMCID:
PMC11841085
ArticlePDF–1.1M
12.
Psychiatric disorders in adolescent and young adult cancer survivors in Korea
S.-M. Jeong, D. Kang, H. Kim, K.H. Jeon, H.L. Choi, H.Y. Park, S. Kim, J. Cho, D.W. Shin
ESMO Open. 2025 Feb; 10(2): 104101. Published online 2025 Jan 27. doi: 10.1016/j.esmoop.2024.104101
PMCID:
PMC11808613
ArticlePDF–511K
13.
Health networking on cancer in the European Union: a ‘green paper’ by the EU Joint Action on Networks of Expertise (JANE)
P.G. Casali, H. Antoine-Poirel, S. Berrocoso, J.-Y. Blay, T. Dubois, A. Ferrari, A. Fullaondo, E. Hovig, P. Jagodzińska-Mucha, I. Ługowska, S. Kaasa, D. Nicoară, V. Pletsa, S. Provenzano, M. Santoro, M. Šekerija, W. Van Hoof, M. Vyas, A. Trama, JANE Consortium
ESMO Open. 2025 Feb; 10(2): 104126. Published online 2025 Jan 27. doi: 10.1016/j.esmoop.2024.104126
PMCID:
PMC11799966
ArticlePDF–319K
14.
BRCA functional domains associated with high risk of multiple primary tumors and domain-related sensitivity to olaparib: the Prometheus Study
L. Incorvaia, C. Marchetti, C. Brando, T.D. Bazan Russo, M. Bono, A. Perez, L. Congedo, R. Ergasti, L. Castellana, L. Insalaco, S. Contino, V. Gristina, A. Galvano, D. Fanale, G. Badalamenti, A. Russo, G. Scambia, V. Bazan
ESMO Open. 2025 Feb; 10(2): 104076. Published online 2025 Jan 22. doi: 10.1016/j.esmoop.2024.104076
PMCID:
PMC11795060
ArticlePDF–716K
15.
Follow-up after first-Line nivOlumab plus ipilimumab in patients with diffuse pleuRal mesotheliomA: a real-world Dutch cohort study—FLORA
L.H. Douma, M.M. Hofman, F. Zwierenga, T.M.T. Zondervan, A.I.G. Buma, H. Schouwink, D.W. Dumoulin, J.A. Burgers, I. Smesseim, J.G.J.V. Aerts, C.J. de Gooijer
ESMO Open. 2025 Feb; 10(2): 104123. Published online 2025 Jan 21. doi: 10.1016/j.esmoop.2024.104123
PMCID:
PMC11794158
ArticlePDF–614K
16.
Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges
I. Schlam, S. Loi, R. Salgado, S.M. Swain
ESMO Open. 2025 Feb; 10(2): 104120. Published online 2025 Jan 17. doi: 10.1016/j.esmoop.2024.104120
PMCID:
PMC11786075
ArticlePDF–2.6M
17.
HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers
F. Lynce, O. Martínez-Sáez, B. Walbaum, F. Brasó-Maristany, A.G. Waks, P. Villagrasa, G. Villacampa Javierre, E. Sanfeliu, P. Galván, L. Paré, L.M. Anderson, C.M. Perou, J.S. Parker, A. Vivancos, M.K. DiLullo, S. Pernas, E.P. Winer, B. Overmoyer, E.A. Mittendorf, C. Bueno-Muiño, M. Martín, A. Prat, S.M. Tolaney
ESMO Open. 2025 Feb; 10(2): 104100. Published online 2025 Jan 17. doi: 10.1016/j.esmoop.2024.104100
PMCID:
PMC11786065
ArticlePDF–627K
18.
Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes
W. Xu, G. Birch, A. Meliki, V. Moritz, M. Bharadwaj, N.R. Schindler, C. Labaki, R.M. Saliby, K. Dinh, J.T. Horst, M. Sun, S. Kashima, M. Hugaboom, A. Dighe, M. Machaalani, G.-S.M. Lee, M. Hurwitz, B.A. McGregor, M.S. Hirsch, S.A. Shukla, D.F. McDermott, S. Signoretti, R. Romee, T.K. Choueiri, D.A. Braun
ESMO Open. 2025 Feb; 10(2): 104105. Published online 2025 Jan 14. doi: 10.1016/j.esmoop.2024.104105
PMCID:
PMC11783098
ArticlePDF–1.5M
19.
Genomic profiling of intimal sarcoma reveals molecular subtypes with distinct tumor microenvironments and therapeutic implications
C. Park, R. Kim, J.M. Bae, T. Lee, S. Song, Y. Kwak, K.B. Lee, J. Youk, B. Keam, T.M. Kim, D.-W. Kim, J.-I. Kim, J. Choi, M. Kim
ESMO Open. 2025 Jan; 10(1): 104097. Published online 2025 Jan 7. doi: 10.1016/j.esmoop.2024.104097
PMCID:
PMC11758979
ArticlePDF–1.6M
20.
A taxonomy of the factors contributing to the overtreatment of cancer patients at the end of life. What is the problem? Why does it happen? How can it be addressed?
N.I. Cherny, N. Nortjé, R. Kelly, C. Zimmermann, K. Jordan, G. Kreye, N.-S. Le, K.B. Adelson
ESMO Open. 2025 Jan; 10(1): 104099. Published online 2025 Jan 6. doi: 10.1016/j.esmoop.2024.104099
PMCID:
PMC11758828
ArticlePDF–4.0M

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Search details

See more...

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI > Literature > PubMed Central (PMC)
Support Center